Let’s face the facts: so far this century, investing money into GSK PLC (GSK) was like sending it into a black hole. The pharma stock was where money went to die.
That was due to years of poor M&A, as well as financial engineering, at the expense of R&D. That became evident when the global COVID-19 pandemic presented the vaccine powerhouse an opportunity to turn the ship around. But instead, GSK failed to grab a position in the COVID vaccine market.
